Log in with your email address username.


[Comment] HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

In 2017, GlaxoSmithKline announced its intention to withdraw the glucagon-like peptide 1 (GLP-1) receptor agonist albiglutide for commercial reasons. This announcement came before the emergence of definitive evidence regarding the cardiovascular safety and efficacy of albiglutide. In The Lancet, Adrian Hernandez and colleagues1 report results from the Harmony Outcomes trial, which showed, in 9463 participants, that albiglutide has beneficial effects on cardiovascular outcomes when given to people with type 2 diabetes and atherosclerotic cardiovascular disease.